{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:42:17Z","timestamp":1793814137645,"version":"4.6.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12072-024-10716-z","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:07:20Z","timestamp":1723126040000},"page":"1396-1415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3695-9701","authenticated-orcid":false,"given":"Matheus","family":"Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivanna","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Al-Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"issue":"3","key":"10716_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/J.JHEP.2023.04.036","volume":"79","author":"V Wai-Sun Wong","year":"2023","unstructured":"Wai-Sun Wong V, Ekstedt M, Lai-Hung Wong G, Hagstr\u00f6m H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842\u2013852. https:\/\/doi.org\/10.1016\/J.JHEP.2023.04.036","journal-title":"J Hepatol"},{"issue":"2","key":"10716_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/J.JHEP.2023.03.040","volume":"79","author":"MH Le","year":"2023","unstructured":"Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79(2):287\u2013295. https:\/\/doi.org\/10.1016\/J.JHEP.2023.03.040","journal-title":"J Hepatol"},{"issue":"3","key":"10716_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/J.1365-2036.2011.04724.X","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274\u2013285. https:\/\/doi.org\/10.1111\/J.1365-2036.2011.04724.X","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10716_CR4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/GUTJNL-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702. https:\/\/doi.org\/10.1136\/GUTJNL-2023-330595","journal-title":"Gut"},{"issue":"S1","key":"10716_CR5","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(S1):S47\u2013S64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012","journal-title":"J Hepatol"},{"issue":"8","key":"10716_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u2013752. https:\/\/doi.org\/10.1016\/S2468-1253(20)30077-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10716_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/APT.14401","volume":"47","author":"S Sookoian","year":"2018","unstructured":"Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47(1):16\u201325. https:\/\/doi.org\/10.1111\/APT.14401","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10716_CR8","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/J.CGH.2022.06.029","volume":"21","author":"A Tang","year":"2023","unstructured":"Tang A, Ng CH, Phang PH, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs Non-lean NAFLD - a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1750-1760.e12. https:\/\/doi.org\/10.1016\/J.CGH.2022.06.029","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10716_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/J.CGH.2022.11.019","author":"J Ha","year":"2022","unstructured":"Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Published online. 2022. https:\/\/doi.org\/10.1016\/J.CGH.2022.11.019","journal-title":"Clin Gastroenterol Hepatol Published online"},{"issue":"6","key":"10716_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/J.CPCARDIOL.2023.101643","volume":"48","author":"G Bisaccia","year":"2023","unstructured":"Bisaccia G, Ricci F, Khanji MY, et al. Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48(6): 101643. https:\/\/doi.org\/10.1016\/J.CPCARDIOL.2023.101643","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10716_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/LIV.15763","volume":"44","author":"M Souza","year":"2024","unstructured":"Souza M, Diaz I, Barchetta I, Mantovani A. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Liver Int. 2024;44(1):6\u201314. https:\/\/doi.org\/10.1111\/LIV.15763","journal-title":"Liver Int"},{"issue":"3","key":"10716_CR12","doi-asserted-by":"publisher","first-page":"101288","DOI":"10.1016\/J.AOHEP.2024.101288","volume":"29","author":"W Wongtrakul","year":"2024","unstructured":"Wongtrakul W, Charatcharoenwitthaya N, Charatcharoenwitthaya P. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: an updated meta-analysis. Ann Hepatol. 2024;29(3):101288. https:\/\/doi.org\/10.1016\/J.AOHEP.2024.101288","journal-title":"Ann Hepatol"},{"issue":"6","key":"10716_CR13","doi-asserted-by":"publisher","first-page":"102569","DOI":"10.1016\/J.CPCARDIOL.2024.102569","volume":"49","author":"N Nso","year":"2024","unstructured":"Nso N, Mergen D, Ikram M, et al. Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: a comprehensive meta-analysis. Curr Probl Cardiol. 2024;49(6):102569. https:\/\/doi.org\/10.1016\/J.CPCARDIOL.2024.102569","journal-title":"Curr Probl Cardiol"},{"key":"10716_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/S12020-023-03351-5\/TABLES\/3","author":"S Huang","year":"2023","unstructured":"Huang S, Bao Y, Zhang N, Niu R, Tian L. Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis. Endocrine. 2023. https:\/\/doi.org\/10.1007\/S12020-023-03351-5\/TABLES\/3","journal-title":"Endocrine"},{"key":"10716_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/LIV.15880","author":"MB Aboona","year":"2024","unstructured":"Aboona MB, Faulkner C, Rangan P, et al. Disparities among ethnic groups in mortality and outcomes among adults with MASLD: a multicenter study. Liver Int Published online. 2024. https:\/\/doi.org\/10.1111\/LIV.15880","journal-title":"Liver Int Published online"},{"issue":"9","key":"10716_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/APT.17424","volume":"57","author":"K Wijarnpreecha","year":"2023","unstructured":"Wijarnpreecha K, Li F, Lundin SK, et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther. 2023;57(9):1014\u20131027. https:\/\/doi.org\/10.1111\/APT.17424","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10716_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/HEP.0000000000000329","volume":"78","author":"O Nabi","year":"2023","unstructured":"Nabi O, Lapidus N, Boursier J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology. 2023;78(1):272\u2013283. https:\/\/doi.org\/10.1097\/HEP.0000000000000329","journal-title":"Hepatology"},{"issue":"12","key":"10716_CR18","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1002\/HEP4.2081","volume":"6","author":"Y Lan","year":"2022","unstructured":"Lan Y, Lu Y, Li J, et al. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: a cohort study in China. Hepatol Commun. 2022;6(12):3393\u20133405. https:\/\/doi.org\/10.1002\/HEP4.2081","journal-title":"Hepatol Commun"},{"issue":"7","key":"10716_CR19","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.14218\/JCTH.2023.00016","volume":"11","author":"VH Nguyen","year":"2023","unstructured":"Nguyen VH, Ha A, Rouillard NA, et al. Differential mortality outcomes in real-world patients with lean, nonobese, and obese nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2023;11(7):1448\u20131454. https:\/\/doi.org\/10.14218\/JCTH.2023.00016","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"10716_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/S00535-024-02093-Z","volume":"59","author":"SI Wakabayashi","year":"2024","unstructured":"Wakabayashi SI, Tamaki N, Kimura T, Umemura T, Kurosaki M, Izumi N. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease. J Gastroenterol. 2024;59(6):494\u2013503. https:\/\/doi.org\/10.1007\/S00535-024-02093-Z","journal-title":"J Gastroenterol"},{"key":"10716_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/S12876-023-02848-7","author":"S Ishido","year":"2023","unstructured":"Ishido S, Tamaki N, Takahashi Y, et al. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease. BMC Gastroenterol. 2023. https:\/\/doi.org\/10.1186\/S12876-023-02848-7","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"10716_CR22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/JGH3.12808","volume":"6","author":"M Iwaki","year":"2022","unstructured":"Iwaki M, Kessoku T, Tanaka K, et al. Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease. JGH Open. 2022;6(10):696\u2013703. https:\/\/doi.org\/10.1002\/JGH3.12808","journal-title":"JGH Open"},{"issue":"4","key":"10716_CR23","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/J.JHEP.2023.11.015","volume":"80","author":"X Fan","year":"2024","unstructured":"Fan X, Shi Y, Han J, Song Y, Zhao J. Beyond body weight: diversified presentation of MASLD in lean, overweight, and obese participants. J Hepatol. 2024;80(4):e147\u2013e150. https:\/\/doi.org\/10.1016\/J.JHEP.2023.11.015","journal-title":"J Hepatol"},{"key":"10716_CR24","doi-asserted-by":"publisher","unstructured":"Zhou XD, Lonardo A, Pan CQ, et al. Clinical Features and Long-Term Outcomes of Patients Diagnosed with MASLD MAFLD or Both. J Hepatol. https:\/\/doi.org\/10.1016\/J.JHEP.2024.03.039","DOI":"10.1016\/J.JHEP.2024.03.039"},{"issue":"8","key":"10716_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/JAMASURG.2021.0522","volume":"156","author":"BS Brooke","year":"2021","unstructured":"Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156(8):787\u2013788. https:\/\/doi.org\/10.1001\/JAMASURG.2021.0522","journal-title":"JAMA Surg"},{"key":"10716_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/BMJ.N71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372. https:\/\/doi.org\/10.1136\/BMJ.N71","journal-title":"BMJ"},{"issue":"1","key":"10716_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/J.JHEP.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209. https:\/\/doi.org\/10.1016\/J.JHEP.2020.03.039","journal-title":"J Hepatol"},{"issue":"6","key":"10716_CR28","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/J.JHEP.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u20131556. https:\/\/doi.org\/10.1016\/J.JHEP.2023.06.003","journal-title":"J Hepatol"},{"issue":"4","key":"10716_CR29","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/LIV.15856","volume":"44","author":"R Song","year":"2024","unstructured":"Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int. 2024;44(4):1051\u20131060. https:\/\/doi.org\/10.1111\/LIV.15856","journal-title":"Liver Int"},{"issue":"4","key":"10716_CR30","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/J.JHEP.2023.09.033","volume":"80","author":"A Yang","year":"2024","unstructured":"Yang A, Zhu X, Zhang L, Ding Y. Transitioning from NAFLD to MAFLD and MASLD: consistent prevalence and risk factors in a Chinese cohort. J Hepatol. 2024;80(4):e154\u2013e155. https:\/\/doi.org\/10.1016\/J.JHEP.2023.09.033","journal-title":"J Hepatol"},{"issue":"9","key":"10716_CR31","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1177\/0962280219889080","volume":"29","author":"S McGrath","year":"2020","unstructured":"McGrath S, Zhao XF, Steele R, et al. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020;29(9):2520\u20132537. https:\/\/doi.org\/10.1177\/0962280219889080","journal-title":"Stat Methods Med Res"},{"key":"10716_CR32","unstructured":"Wells GA, O\u2019Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp Accessed 22 June 2023"},{"issue":"1","key":"10716_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/JRSM.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361. https:\/\/doi.org\/10.1002\/JRSM.1411","journal-title":"Res Synth Methods"},{"issue":"3","key":"10716_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"issue":"11","key":"10716_CR35","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/SIM.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u20131558. https:\/\/doi.org\/10.1002\/SIM.1186","journal-title":"Stat Med"},{"issue":"7121","key":"10716_CR36","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1136\/BMJ.315.7121.1533","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315(7121):1533\u20131537. https:\/\/doi.org\/10.1136\/BMJ.315.7121.1533","journal-title":"BMJ"},{"issue":"2","key":"10716_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/J.0006-341X.2000.00455.X","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455\u2013463. https:\/\/doi.org\/10.1111\/J.0006-341X.2000.00455.X","journal-title":"Biometrics"},{"issue":"2","key":"10716_CR38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/GUTJNL-2020-322564","volume":"71","author":"R Younes","year":"2022","unstructured":"Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022;71(2):382\u2013390. https:\/\/doi.org\/10.1136\/GUTJNL-2020-322564","journal-title":"Gut"},{"issue":"6","key":"10716_CR39","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/J.CGH.2021.07.016","volume":"20","author":"OT Ahmed","year":"2022","unstructured":"Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study. Clin Gastroenterol Hepatol. 2022;20(6):1374-1381.e6. https:\/\/doi.org\/10.1016\/J.CGH.2021.07.016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10716_CR40","doi-asserted-by":"publisher","first-page":"366","DOI":"10.15403\/JGLD-3622","volume":"30","author":"A Feldman","year":"2021","unstructured":"Feldman A, Wernly B, Strebinger G, et al. Liver-related mortality is increased in lean subjects with non- alcoholic fatty liver disease compared to overweight and obese subjects. J Gastrointestin Liver Dis. 2021;30(3):366\u2013373. https:\/\/doi.org\/10.15403\/JGLD-3622","journal-title":"J Gastrointestin Liver Dis"},{"issue":"9","key":"10716_CR41","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/CLINEM\/DGAB339","volume":"106","author":"G Semmler","year":"2021","unstructured":"Semmler G, Wernly S, Bachmayer S, et al. Metabolic dysfunction-associated fatty liver disease (MAFLD)-rather a bystander than a driver of mortality. J Clin Endocrinol Metab. 2021;106(9):2670\u20132677. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB339","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10716_CR42","doi-asserted-by":"publisher","first-page":"e0245762","DOI":"10.1371\/JOURNAL.PONE.0245762","volume":"16","author":"MA Niriella","year":"2021","unstructured":"Niriella MA, Ediriweera DS, Kasturiratne A, et al. Outcomes of NAFLD and MAFLD: Results from a community-based prospective cohort study. PLoS ONE. 2021;16(2):e0245762. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0245762","journal-title":"PLoS ONE"},{"issue":"1","key":"10716_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/JOIM.13069","volume":"288","author":"B Zou","year":"2020","unstructured":"Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999\u20132016. J Intern Med. 2020;288(1):139\u2013151. https:\/\/doi.org\/10.1111\/JOIM.13069","journal-title":"J Intern Med"},{"issue":"8","key":"10716_CR44","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/HEP4.1534","volume":"4","author":"P Golabi","year":"2020","unstructured":"Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM. Mortality of NAFLD according to the body composition and presence of metabolic abnormalities. Hepatol Commun. 2020;4(8):1136. https:\/\/doi.org\/10.1002\/HEP4.1534","journal-title":"Hepatol Commun"},{"key":"10716_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/S12876-020-01509-3","author":"S Iritani","year":"2020","unstructured":"Iritani S, Akuta N, Kawamura Y, et al. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. BMC Gastroenterol. 2020. https:\/\/doi.org\/10.1186\/S12876-020-01509-3","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10716_CR46","doi-asserted-by":"publisher","first-page":"620","DOI":"10.14309\/AJG.0000000000000074","volume":"114","author":"Y Chang","year":"2019","unstructured":"Chang Y, Cho YK, Cho J, et al. Alcoholic and nonalcoholic fatty liver disease and liver-related mortality: a cohort study. Am J Gastroenterol. 2019;114(4):620\u2013629. https:\/\/doi.org\/10.14309\/AJG.0000000000000074","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10716_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/HEP4.1124","volume":"2","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2017;2(1):48\u201357. https:\/\/doi.org\/10.1002\/HEP4.1124","journal-title":"Hepatol Commun"},{"issue":"1","key":"10716_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/HEP.28697","volume":"65","author":"JCF Leung","year":"2017","unstructured":"Leung JCF, Loong TCW, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65(1):54\u201364. https:\/\/doi.org\/10.1002\/HEP.28697","journal-title":"Hepatology"},{"issue":"11","key":"10716_CR49","doi-asserted-by":"publisher","first-page":"e0241770","DOI":"10.1371\/JOURNAL.PONE.0241770","volume":"15","author":"S Hirose","year":"2020","unstructured":"Hirose S, Matsumoto K, Tatemichi M, et al. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. PLoS ONE. 2020;15(11):e0241770. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0241770","journal-title":"PLoS ONE"},{"issue":"4","key":"10716_CR50","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/HEP.30908","volume":"71","author":"F Chen","year":"2020","unstructured":"Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology. 2020;71(4):1213\u20131227. https:\/\/doi.org\/10.1002\/HEP.30908","journal-title":"Hepatology"},{"issue":"10","key":"10716_CR51","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/S41575-022-00635-5","volume":"19","author":"M Eslam","year":"2022","unstructured":"Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638\u2013651. https:\/\/doi.org\/10.1038\/S41575-022-00635-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10716_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/J.METABOL.2023.155583","volume":"144","author":"J Alharthi","year":"2023","unstructured":"Alharthi J, Pan Z, Gloss BS, et al. Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism. 2023;144: 155583. https:\/\/doi.org\/10.1016\/J.METABOL.2023.155583","journal-title":"Metabolism"},{"issue":"4","key":"10716_CR53","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/HEP.32047","volume":"74","author":"S Vilarinho","year":"2021","unstructured":"Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Hepatology. 2021;74(4):2241\u20132250. https:\/\/doi.org\/10.1002\/HEP.32047","journal-title":"Hepatology"},{"issue":"11","key":"10716_CR54","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/LIV.15377","volume":"42","author":"C Saponaro","year":"2022","unstructured":"Saponaro C, Sabatini S, Gaggini M, et al. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. Liver Int. 2022;42(11):2418\u20132427. https:\/\/doi.org\/10.1111\/LIV.15377","journal-title":"Liver Int"},{"issue":"2","key":"10716_CR55","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/J.1365-2036.2011.04929.X","volume":"35","author":"S Petta","year":"2012","unstructured":"Petta S, Amato MC, Di Marco V, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35(2):238\u2013247. https:\/\/doi.org\/10.1111\/J.1365-2036.2011.04929.X","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10716_CR56","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/NRENDO.2016.221","volume":"13","author":"N Perakakis","year":"2017","unstructured":"Perakakis N, Triantafyllou GA, Fern\u00e1ndez-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324\u2013337. https:\/\/doi.org\/10.1038\/NRENDO.2016.221","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10716_CR57","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/HEP.30049","volume":"68","author":"G Kim","year":"2018","unstructured":"Kim G, Lee SE, Bin LY, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology. 2018;68(5):1755\u20131768. https:\/\/doi.org\/10.1002\/HEP.30049","journal-title":"Hepatology"},{"issue":"4","key":"10716_CR58","doi-asserted-by":"publisher","first-page":"584","DOI":"10.14309\/AJG.0000000000000572","volume":"115","author":"E Han","year":"2020","unstructured":"Han E, Lee YH, Kim YD, et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am J Gastroenterol. 2020;115(4):584\u2013595. https:\/\/doi.org\/10.14309\/AJG.0000000000000572","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10716_CR59","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.3390\/NU15102254","volume":"15","author":"GA Bray","year":"2023","unstructured":"Bray GA. BMI beyond. Nutrients. 2023;15(10):2254. https:\/\/doi.org\/10.3390\/NU15102254","journal-title":"Nutrients"},{"issue":"12","key":"10716_CR60","doi-asserted-by":"publisher","first-page":"101592","DOI":"10.1016\/J.DISAMONTH.2023.101592","volume":"69","author":"Y Zou","year":"2023","unstructured":"Zou Y, Pitchumoni CS. Obesity, obesities and gastrointestinal cancers. Dis Mon. 2023;69(12):101592. https:\/\/doi.org\/10.1016\/J.DISAMONTH.2023.101592","journal-title":"Dis Mon"},{"issue":"2","key":"10716_CR61","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/J.JHEP.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268\u2013279. https:\/\/doi.org\/10.1016\/J.JHEP.2017.09.003","journal-title":"J Hepatol"},{"issue":"10","key":"10716_CR62","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1111\/LIV.15678","volume":"43","author":"Y Seko","year":"2023","unstructured":"Seko Y, Yamaguchi K, Shima T, et al. The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: a multicentre cohort study. Liver Int. 2023;43(10):2210\u20132219. https:\/\/doi.org\/10.1111\/LIV.15678","journal-title":"Liver Int"},{"issue":"6","key":"10716_CR63","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/NG.3855","volume":"49","author":"S Stender","year":"2017","unstructured":"Stender S, Kozlitina J, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017;49(6):842\u2013847. https:\/\/doi.org\/10.1038\/NG.3855","journal-title":"Nat Genet"},{"issue":"1","key":"10716_CR64","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/LIV.15078","volume":"42","author":"H Lin","year":"2022","unstructured":"Lin H, Wong GLH, Whatling C, et al. Association of genetic variations with NAFLD in lean individuals. Liver Int. 2022;42(1):149\u2013160. https:\/\/doi.org\/10.1111\/LIV.15078","journal-title":"Liver Int"},{"key":"10716_CR65","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/J.ATHEROSCLEROSIS.2019.01.029","volume":"282","author":"RD Santos","year":"2019","unstructured":"Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current Knowledge Gaps Atherosclerosis. 2019;282:110\u2013120. https:\/\/doi.org\/10.1016\/J.ATHEROSCLEROSIS.2019.01.029","journal-title":"Current Knowledge Gaps Atherosclerosis"},{"issue":"4","key":"10716_CR66","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/J.NUMECD.2017.10.014","volume":"28","author":"SMB Duarte","year":"2018","unstructured":"Duarte SMB, Stefano JT, Miele L, et al. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study. Nutr Metab Cardiovasc Dis. 2018;28(4):369\u2013384. https:\/\/doi.org\/10.1016\/J.NUMECD.2017.10.014","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10716_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep32002","volume":"6","author":"B Wang","year":"2016","unstructured":"Wang B, Jiang X, Cao M, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6(1):1\u201311. https:\/\/doi.org\/10.1038\/srep32002","journal-title":"Sci Rep"},{"issue":"6","key":"10716_CR68","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/S12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889\u2013919. https:\/\/doi.org\/10.1007\/S12072-020-10094-2","journal-title":"Hepatol Int"},{"issue":"2","key":"10716_CR69","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/J.JHEP.2023.07.031","volume":"80","author":"A De","year":"2024","unstructured":"De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. J Hepatol. 2024;80(2):e61\u2013e62. https:\/\/doi.org\/10.1016\/J.JHEP.2023.07.031","journal-title":"J Hepatol"},{"issue":"3","key":"10716_CR70","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/J.GASTRO.2022.06.023","volume":"163","author":"MT Long","year":"2022","unstructured":"Long MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology. 2022;163(3):764-774.e1. https:\/\/doi.org\/10.1053\/J.GASTRO.2022.06.023","journal-title":"Gastroenterology"},{"issue":"1","key":"10716_CR71","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/HEP.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67(1):328\u2013357. https:\/\/doi.org\/10.1002\/HEP.29367","journal-title":"Hepatology"},{"issue":"6","key":"10716_CR72","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/J.JHEP.2018.08.011","volume":"69","author":"VWS Wong","year":"2018","unstructured":"Wong VWS, Wong GLH, Chan RSM, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69(6):1349\u20131356. https:\/\/doi.org\/10.1016\/J.JHEP.2018.08.011","journal-title":"J Hepatol"},{"issue":"5","key":"10716_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS22052350","volume":"22","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Dalbeni A. Treatments for NAFLD: State of art. Int J Mol Sci. 2021;22(5):1\u201327. https:\/\/doi.org\/10.3390\/IJMS22052350","journal-title":"Int J Mol Sci"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10716-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10716-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10716-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T15:08:21Z","timestamp":1728400101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10716-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10716"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10716-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"20 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}